Lupin Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has signed a licensing and supply agreement with Zydus Lifesciences to co-market Zydus' innovative Semaglutide Injection (15 mg/3 ml) with a reusable pen device in India. Under the deal, Lupin gets semi-exclusive rights to market the product under the brand names Semanext® and Livarise®, while Zydus retains marketing under SEMAGLYN™, MASHEMA™ and ALTERME™. Lupin will pay Zydus upfront licensing fees and milestone payments, though specific financial terms were not disclosed. The product targets type 2 diabetes and chronic weight management (obesity/overweight), placing Lupin in the high-demand GLP-1 therapy segment.
This deal strengthens Lupin's diabetes and cardio-metabolic portfolio by adding a marquee GLP-1 therapy at a time of surging demand for weight-loss and diabetes drugs in India. The licensing model allows Lupin to participate in this fast-growing segment without bearing full R&D risk, which is likely to be viewed positively by investors.